Glandokort is a "Cytomax" class peptide bioregulator designed to restore the function of the adrenal glands. Unlike cortisol replacement therapy or adaptogenic herbs, Glandokort acts as an epigenetic modulator, triggering the synthesis of tissue-specific proteins within the adrenal cortex to repair and rejuvenate the gland itself.
Derived from the adrenal glands of young calves or pigs, it is part of the Khavinson Bioregulator family developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is primarily used to combat "adrenal fatigue," chronic burnout, and the hormonal dysregulation associated with aging.
Glandokort is a complex of polypeptide fractions (Code A-17) extracted from adrenal tissue. It is not a hormone; it contains no cortisol, adrenaline, or synthetic steroids. Instead, it provides the "genetic keys" to instruct adrenal cells to repair themselves and function optimally.
Glandokort offers a unique value proposition: it repairs the hardware (the adrenal gland) rather than supplementing the software (hormones). This makes it a safer long-term strategy than Hormone Replacement Therapy (HRT) for mild-to-moderate adrenal dysfunction, as it does not downregulate the body's natural production.
Goal: Restore adrenal tissue integrity and normalize cortisol output.
Notes:
While "adrenal fatigue" is a controversial term in Western medicine (often preferring "HPA axis dysfunction"), the symptoms of burnout—fatigue, apathy, sleep disturbances, and inability to handle stress—are clinically real. Glandokort targets the cellular basis of these symptoms. By restoring protein synthesis in the adrenal cortex, it helps the gland maintain adequate reserves of cortisol and catecholamines (adrenaline/noradrenaline) without exhaustion.
Unlike hydrocortisone, which indiscriminately raises cortisol, Glandokort acts as a bioregulator (normalizer).
The adrenal glands play a critical role in metabolism via cortisol (glucose regulation) and aldosterone (electrolyte balance). Users often report improved energy stability and reduced "crashes" throughout the day, likely due to more stable glycemic control mediated by healthy adrenal function.

Glandokort operates on the principle of peptide bioregulation discovered by Vladimir Khavinson.
This mechanism explains why Glandokort is effective for both overactive and underactive adrenals—it optimizes the cell's capacity to function, rather than forcing a specific output[2].
Most research on Glandokort has been conducted in Russia. Key findings include:
As a Cytomax (natural extract), Glandokort has an exceptional safety profile.
Khavinson VK, Kuznik BI, Ryzhak GA. Peptide Bioregulators: A New Class of Geroprotectors. Advances in Gerontology. 2014. ↩︎ ↩︎
Khavinson VK. Peptides and Ageing. Neuroendocrinology Letters. 2002. ↩︎
Khavinson VK, et al. Effects of short peptides on adrenal gland function in conditions of acute and chronic stress. Bulletin of Experimental Biology and Medicine. 2012. ↩︎